Healthy people get first dose of experimental exosome drug
NCT ID NCT07219940
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 35 times
Summary
This early-stage study tests a new drug called SOB100 in 15 healthy adults. SOB100 is a tiny particle (exosome) designed to target a protein called HLA-G. The main goal is to check if it is safe and how the body processes it. No treatment benefit is expected for participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Parexel International - Baltimore Early Phase Clinical Unit
RECRUITINGBaltimore, Maryland, 21225, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.